Edotecarin is used as a potent topoisomerase I inhibitor for anticancer therapy; it demonstrates significant antitumor activity against human colon cancer cells by inducing DNA-protein complex formation and single-strand DNA breaks; it shows strong antimetastatic effects and prolongs survival in mice bearing intracranial D-456MG glioma; it causes dose-dependent tumor growth delay; and it exhibits enhanced antitumor efficacy in combination with irinotecan compared to either agent alone.